ArticleInnovation (Cambridge (Mass.))2025

Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trial.

Yu Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.